Discovery and Characterization of VU0529331, a Synthetic Small-Molecule Activator of Homomeric G Protein-Gated, Inwardly Rectifying, Potassium (GIRK) Channels

• Published in: ACS chemical neuroscience Vol. 10; no. 1; pp. 358 - 370
• Main Authors: Kozek, Krystian A, Du, Yu, Sharma, Swagat, Prael, Francis J, Spitznagel, Brittany D, Kharade, Sujay V, Denton, Jerod S, Hopkins, Corey R, Weaver, C. David
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 16.01.2019
• Subjects: Dose-Response Relationship, Drug; Drug Discovery - methods; G Protein-Coupled Inwardly-Rectifying Potassium Channels - agonists; G Protein-Coupled Inwardly-Rectifying Potassium Channels - metabolism; HEK293 Cells; Humans; Ion Channel Gating - drug effects; Ion Channel Gating - physiology; Neurons - drug effects; Neurons - metabolism; Pyrazines - chemistry; Pyrazines - pharmacology; GIRK channel; small molecule; modulator; whole-cell patch-clamp electrophysiology; ion channel; high-throughput screening; activator; Kir3; thallium flux assay; GIRK2
• DOI: 10.1021/acschemneuro.8b00287
• ISSN: 1948-7193

G protein-gated, inwardly rectifying, potassium (GIRK) channels are important regulators of cellular excitability throughout the body. GIRK channels are heterotetrameric and homotetrameric combinations of the Kir3.1–4 (GIRK1–4) subunits. Different subunit combinations are expressed throughout the central nervous system (CNS) and the periphery, and most of these combinations contain a GIRK1 subunit. For example, the predominance of GIRK channels in the CNS are composed of GIRK1 and GIRK2 subunits, while the GIRK channels in cardiac atrial myocytes are made up mostly of GIRK1 and GIRK4 subunits. Although the vast majority of GIRK channels contain a GIRK1 subunit, discrete populations of cells that express non-GIRK1-containing GIRK (non-GIRK1/X) channels do exist. For instance, dopaminergic neurons in the ventral tegmental area of the brain, associated with addiction and reward, do not express the GIRK1 subunit. Targeting these non-GIRK1/X channels with subunit-selective pharmacological probes could lead to important insights into how GIRK channels are involved in reward and addiction. Such insights may, in turn, reveal therapeutic opportunities for the treatment or prevention of addiction. Previously, our laboratory discovered small molecules that can specifically modulate the activity of GIRK1-containing GIRK channels. However, efforts to generate compounds active on non-GIRK1/X channels from these scaffolds have been unsuccessful. Recently, ivermectin was shown to modulate non-GIRK1/X channels, and historically, ivermectin is known to modulate a wide variety of neuronal channels and receptors. Further, ivermectin is a complex natural product, which makes it a challenging starting point for development of more selective, effective, and potent compounds. Thus, while ivermectin provides proof-of-concept as a non-GIRK1/X channel activator, it is of limited utility. Therefore, we sought to discover a synthetic small molecule that would serve as a starting point for the development of non-GIRK1/X channel modulators. To accomplish this, we used a high-throughput thallium flux assay to screen a 100 000-compound library in search of activators of homomeric GIRK2 channels. Using this approach, we discovered VU0529331, the first synthetic small molecule reported to activate non-GIRK1/X channels, to our knowledge. This discovery represents the first step toward developing potent and selective non-GIRK1/X channel probes. Such molecules will help elucidate the role of GIRK channels in addiction, potentially establishing a foundation for future development of therapies utilizing targeted GIRK channel modulation.